8-KEarnings & ResultsExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (Jan 11, 2021)

Filed January 11, 2021For Securities:DXCM

Summary

DEXCOM INC (DXCM) filed an 8-K on January 11, 2021, to provide preliminary, unaudited financial results and its initial outlook for fiscal year 2021. The company anticipates strong year-over-year revenue growth, with fourth-quarter 2020 revenue expected to meet or exceed $567 million, representing a 23% increase compared to the prior year. For the full fiscal year 2020, total preliminary revenue is projected to exceed $1.925 billion, a growth of over 30% from 2019. Looking ahead to fiscal year 2021, DexCom provided an initial revenue outlook in the range of $2.21 billion to $2.31 billion, indicating continued growth expectations. Investors should note that these figures are preliminary and unaudited, subject to finalization in DexCom's Form 10-K. The filing also includes forward-looking statements regarding future performance and potential risks and uncertainties that could impact actual results.

Key Highlights

  • 1Preliminary Q4 2020 revenue expected to meet or exceed $567 million, up 23% year-over-year.
  • 2Full fiscal year 2020 preliminary revenue projected to exceed $1.925 billion, representing over 30% growth from 2019.
  • 3Initial fiscal year 2021 revenue outlook provided, ranging from $2.21 billion to $2.31 billion.
  • 4These financial results are preliminary and unaudited, subject to finalization.
  • 5Forward-looking statements regarding future expectations and potential risks are included.
  • 6Information was presented during the J.P. Morgan Virtual 39th Annual Healthcare Conference.
  • 7A press release, attached as Exhibit 99.01, details these preliminary results and outlook.

Frequently Asked Questions

DexCom's preliminary, unaudited revenue for the fourth quarter ended December 31, 2020, was expected to meet or exceed $567 million, a 23% increase compared to Q4 2019.

For fiscal year 2021, DexCom provided an initial financial outlook anticipating total revenue in the range of $2.21 billion to $2.31 billion.

No, the financial results reported in this 8-K filing are preliminary and unaudited. They are subject to finalization during the preparation of DexCom's Annual Report on Form 10-K for the twelve months ended December 31, 2020.

The filing mentions that forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. These risks are more fully described in DexCom's previous SEC filings, including its 2019 Form 10-K and its most recent Form 10-Q for the period ended September 30, 2020.